Neurocrine Biosciences (NBIX) Starts Phase 2 Alzheimer’s Trial

What happened: Neurocrine Biosciences (NasdaqGS:NBIX) began a Phase 2 trial of NBI-1117567 in adults with mild to moderate Alzheimer's disease. The orally administered muscarinic receptor agonist targets cognitive impairment linked to Alzheimer's symptoms. Key numbers: Market cap $14.4b. Why it matters: The trial fits Neurocrine's muscarinic franchise ambition but is mid stage and behind its late stage psychiatry assets, leaving questions on commercial scale unanswered. The company also cited a VYKAT XR publication on Prader-Willi syndrome. Market: +1.4% today ($143.29), +1.9% YTD, 1.0x vol — as of 22:46 UTC

Neurocrine Biosciences (NasdaqGS:NBIX) began a Phase 2 trial of NBI-1117567 in adults with mild to moderate Alzheimer's disease. The orally administered muscarinic receptor agonist targets cognitive impairment linked to Alzheimer's symptoms.

The trial fits Neurocrine's muscarinic franchise ambition but is mid stage and behind its late stage psychiatry assets, leaving questions on commercial scale unanswered. The company also cited a VYKAT XR publication on Prader-Willi syndrome. Market: +1.4% today ($143.29), +1.9% YTD, 1.0x vol — as of 22:46 UTC